Ras, PI(3)K and mTOR signalling controls tumour cell growth
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
All eukaryotic cells coordinate cell growth with the availability of nutrients in their environment. The mTOR protein kinase has emerged as a critical growth-control node, receiving stimulatory signals from Ras and phosphatidylinositol-3-OH kinase (PI(3)K) downstream from growth factors, as well as nutrient inputs in the form of amino-acid, glucose and oxygen availability. Notably, components of the Ras and PI(3)K signalling pathways are mutated in most human cancers. The preponderance of mutations in these interconnected pathways suggests that the loss of growth-control checkpoints and promotion of cell survival in nutrient-limited conditions may be an obligate event in tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
From Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth (2008) · cites this paper as [13]
In the citing paper
“PI3K signaling may be central to linking the common genetic perturbations of cancer, such as RTK mutations and PTEN loss, with altered metabolic processes, including the “lipogenic phenotype” common to many cancers, including GBM (13, 14, 17, 20).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [20]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 8×
“So, the PI(3)K heterodimer is recruited to the membrane to generate local pools of PtdIns(3,4,5)P3.”
BackgroundInfluentialAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · cited 1×
“AMPK inhibits mTOR at least in part by the direct phosphorylation of tuberin ( Box 3 ), and cells that lack tuberin retain activated mTORC1 under conditions of low glucose as well as hypoxi”
BackgroundRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 1×
“In addition to loss of RasGAP function, Ras activity is reported to be elevated through reduced expression of a conserved microRNA (let-7) that targets the 3′ untranslated region of H-ras, N-ras and K-ras messenger RNA”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · cited 1×
“PTEN catalyses removal of the D3 phosphate from PtdIns(3,4,5)P 3 (the reverse of the reaction catalysed by PI(3)K) to limit and ultimately terminate PI(3)K signalling in cell”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“The existence of the S6K-based negative-feedback loop means that prolonged rapamycin treatment will probably lead to enhanced PI(3)K–AKT activation in some tumours, as has been observed in several tumour cell lines grown in culture, and in tissues from patients in clinical trials of rapamycin analogue”
Background
Cited by
Items 301–400 of 1,006
Palaskas, N., Larson, S. M., Schultz, N., Komisopoulou, E., Wong, J., Rohle, D., Campos, C., Yannuzzi, N., Osborne, J. R., Linkov, I., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4633 · Cited by 121
“S4B and C), a target of Akt and readout for PI3K pathway activity (42).”
BackgroundInfluentialIdentification of an oncogenic RAB protein
Wheeler, D. B., Zoncu, R., Root, D. E., Sabatini, D. M., & Sawyers, C. L. (2015) · Science · doi:10.1126/science.aaa4903 · Cited by 124
Regulation of Food Intake Through Hypothalamic Signaling Networks Involving mTOR
Woods, S. C., Seeley, R. J., & Cota, D. (2008) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.28.061807.155505 · Cited by 125
Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Totiger, T. M., Srinivasan, S., Jala, V. R., Lamichhane, P., Dosch, A. R., Gaidarski, A. A., Joshi, C., Rangappa, S., Castellanos, J., Vemula, P. K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0464 · Cited by 121
“The PI3K signaling pathway is a downstream effector of oncogenic KRAS (35), which is nearly ubiquitous in PDAC.”
BackgroundPI3K Signaling in Glioma—Animal Models and Therapeutic Challenges
Cheng, C. K., Fan, Q., & Weiss, W. A. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00233.x · Cited by 141
“Akt phosphorylation and subsequent inactivation of GSK-3 stabilizes these cell cycle regulatory proteins and drives proliferation (55).”
BackgroundLiu, Z., Li, X., Simoneau, A. R., Jafari, M., & Zi, X. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.20780 · Cited by 117
Semenas, J., Hedblom, A., Miftakhova, R. R., Sarwar, M., Larsson, R., Shcherbina, L., Johansson, M. E., Härkönen, P., Sterner, O., & Persson, J. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405801111 · Cited by 115
“Given that amplification of AKT2 or mutations in PIK3CA, in addition to PTEN mutation, are all responsible for activation of PI3K pathway (15, 38, 39), our data suggest that ISA2011B exerts its on-target effect on PCa cells by targeting pathways related to AKT/AR, rather than a toxic effect.”
BackgroundInfluentialPTEN mutation, methylation and expression in breast cancer patients
Zhang, H., LIANG, F., Zhi-ling, J., Song, S., & Jiang, Z. (2013) · Oncology Letters · doi:10.3892/ol.2013.1331 · Cited by 142
“The PI3K signaling pathway is associated with almost all aspects of tumor biology, including cell transformation, growth, proliferation, migration and apoptosis evasion and genomic instability, angiogenesis, metastasis and cancer stem cell maintenance (21,22).”
Activation and Function of the mTORC1 Pathway in Mast Cells
Kim, M.-S., Kuehn, H. S., Metcalfe, D. D., & Gilfillan, A. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4586 · Cited by 120
Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways
Chen, X., Liu, F., Song, X., Wang, Z., Dong, Z., Hu, Z., Lan, R., Guan, W., Zhou, T., Xu, X., et al. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20628 · Cited by 125
“accepted that mTORC1 is strongly inhibited by rapamycin, whereas mTORC2 is insensitive to the rapamycin [6].”
BackgroundThe splicing-factor oncoprotein SF2/ASF activates mTORC1
Karni, R., Hippo, Y., Lowe, S. W., & Krainer, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801376105 · Cited by 124
“Akt, a major effector of the PI3K pathway, is both an upstream activator of mTOR and a substrate of mTORC2 (2, 3, 13).”
BackgroundInfluentialThe nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53
Lee, S.-O., Andey, T., Jin, U.-H., Kim, K., Sachdeva, M., & Safe, S. (2012) · Oncogene · doi:10.1038/onc.2011.504 · Cited by 122
“…has become an increasingly important target for anticancer drugs such as rapamycin because of its central role in regulating multiple downstream pro-oncogenic factors (Bjornsti and Houghton, 2004; Hay and Sonenberg, 2004; Shaw and Cantley, 2006; Guertin and Sabatini, 2007; Yang and Guan, 2007).”
The Role of CNS Fuel Sensing in Energy and Glucose Regulation
Cota, D., Proulx, K., & Seeley, R. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.049 · Cited by 128
“effects of AgRP-(83-132) involve mechanisms other than mela-”
BackgroundTrovik, J., Wik, E., Stefansson, I. M., Marcickiewicz, J., Tingulstad, S., Staff, A. C., Njølstad, T. S., MoMaTec Study Group, Vandenput, I., Amant, F. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2412 · Cited by 121
Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies
Barrett, D., Brown, V. I., Grupp, S. A., & Teachey, D. T. (2012) · Pediatric Drugs · doi:10.1007/bf03262236 · Cited by 130
“mTOR is activated by a number of signaling pathways, including PI3K/AKT, as well as RAS, BCR-ABL, and (T-cell leukemia/lymphoma 1 (TCL1).([28,29]) mTOR can form two distinct complexes, mTORC1 and mTORC2.”
Carbognin, L., Miglietta, F., Paris, I., & Dieci, M. V. (2019) · Cancers · doi:10.3390/cancers11091401 · Cited by 123
Amino acid management in cancer
Tsun, Z.-Y., & Possemato, R. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.08.002 · Cited by 112
Ras oncogenes in oral cancer: The past 20 years
Murugan, A. K., Munirajan, A. K., & Tsuchida, N. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2011.12.006 · Cited by 129
Therapeutic targeting of the mTOR ‐signalling pathway in cancer: benefits and limitations
Moschetta, M., Reale, A., Marasco, C., Vacca, A., & Carratù, M. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12749 · Cited by 128
“This critical task is achieved by Akt phosphorylation and up- or down-regulation of other key proteins (Shaw and Cantley, 2006).”
BackgroundAnticancer effects of oleuropein
Shamshoum, H., Vlavcheski, F., & Tsiani, E. (2017) · BioFactors · doi:10.1002/biof.1366 · Cited by 120
“Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that is responsible for sensing and integrating numerous environmental and nutritional signals and when activated leads to increased protein synthesis, proliferation, and survival [11,12].”
BackgroundWang, T.-C., Hudson, T., Wang, T.-C., Remsberg, C. M., Davies, N. M., Takahashi, Y., Kim, Y. S., Seifried, H. E., Vinyard, B. T., Perkins, S. N., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn131 · Cited by 125
“In addition, several messenger RNAs (mRNAs) coding for genes involved in the AKT-mediated pathway (36, 37 ) were also affected by exposure to resveratrol.”
BackgroundInfluentialGenomic Complexity and AKT Dependence in Serous Ovarian Cancer
Hanrahan, A. J., Schultz, N., Westfal, M. L., Sakr, R. A., Giri, D. D., Scarperi, S., Janikariman, M., Olvera, N., Stevens, E. V., She, Q.-B., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0170 · Cited by 114
Cheng, J., & Du, J. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.147371 · Cited by 114
Oncogenic mutations as predictive factors in colorectal cancer
Lièvre, A., Blons, H., & Laurent-Puig, P. (2010) · Oncogene · doi:10.1038/onc.2010.89 · Cited by 117
Tumor Biology and Prognostic Factors in Renal Cell Carcinoma
Finley, D. S., Pantuck, A. J., & Belldegrun, A. S. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s2-04 · Cited by 132
Pan, S., Zhang, Y., Huang, M., Deng, Z., Zhang, A., Pei, L., Wang, L., Zhao, W., Ma, L., Zhang, Q., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120946 · Cited by 125
Teachey, D. T., Grupp, S. A., & Brown, V. I. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07657.x · Cited by 121
“…remains unclear, and seems to vary by cell type. mTOR is activated by a number of upstream signalling pathways, including PI3K/AKT, RAS/ MAPK/RSK, cytokine signalling (IKK), TCL1, BCR-ABL, and nutrient (amino acid) sensing via the Rag GTP-binding proteins (Shaw & Cantley, 2006; Kharas et al, 2008).”
BackgroundThe Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer
Lauring, J. D., Park, B. H., & Wolff, A. C. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0086 · Cited by 126
Van Meter, M. E. M., Díaz-Flores, E., Archard, J. A., Passegué, E., Irish, J. M., Kotecha, N., Nolan, G. P., Shannon, K., & Braun, B. S. (2007) · Blood · doi:10.1182/blood-2006-09-047530 · Cited by 114
Nederlof, R., Eerbeek, O., Hollmann, M. W., Southworth, R., & Zuurbier, C. J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12363 · Cited by 120
“Activation of the PI3K/Akt pathway, one of the most frequently mutated pathways in cancer (Shaw and Cantley, 2006), and activation of PKA and PKC pathways, also commonly seen in cancers, may explain this increased HKII expression.”
BackgroundForkhead Transcription Factors in Health and Disease
Herman, L., Todeschini, A., & Veitia, R. A. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.11.003 · Cited by 121
Hypoxia in cancer cell metabolism and pH regulation
Brahimi-Horn, M. C., & Pouysségur, J. (2007) · Essays in Biochemistry · doi:10.1042/bse0430165 · Cited by 113
“HIF-1 and nutrient deprivation also negatively regulate ATP-consuming protein translation by inhibition of the mTOR pathway [7,37], thus promoting cell survival through energy conservation.”
BackgroundEmerging molecular targets in melanoma invasion and metastasis
Orgaz, J. L., & Sanz‐Moreno, V. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12041 · Cited by 127
“RAS signals through a number of effectors, especially those in the RAF/MEK/ERK pathway and the phosphoinositide-3-OH kinase (PI3K) pathway, thereby affecting cell proliferation, survival, migration and invasion (Gray-Schopfer et al., 2007a; Shaw and Cantley, 2006).”
BackgroundPI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma
Petrulea, M. S., Plantinga, T. S., Smit, J. W. A., Georgescu, C. E., & Netea-Maier, R. T. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.06.005 · Cited by 124
“mTOR is present in the form of two protein complexes: mTORC1 and mTORC2 [34].”
BackgroundOvercoming apoptosis deficiency of melanoma—Hope for new therapeutic approaches
Eberle, J., Kurbanov, B. M., Hossini, A. M., Trefzer, U., & Fecker, L. F. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.09.001 · Cited by 122
Ono, M., Ohkouchi, S., Kanehira, M., Tode, N., Kobayashi, M., Ebina, M., Nukiwa, T., Irokawa, T., Ogawa, H., Akaike, T., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.217 · Cited by 111
Marzec, M., Kasprzycka, M., Liu, X., El-Salem, M., Halasa, K., Raghunath, P. N., Bucki, R., Wlodarski, P. K., & Wasik, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210346 · Cited by 118
AKT Signaling Pathway in the Nucleus Accumbens Mediates Excessive Alcohol Drinking Behaviors
Neasta, J., Ben Hamida, S., Yowell, Q. V., Carnicella, S., & Ron, D. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.03.019 · Cited by 104
MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization
Vagima, Y., Avigdor, A., Goichberg, P., Shivtiel, S., Tesio, M., Kalinkovich, A., Golan, K., Dar, A., Kollet, Ó., Petit, I., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36541 · Cited by 115
Ho, Y., & Gasch, A. P. (2015) · Current Genetics · doi:10.1007/s00294-015-0491-0 · Cited by 120
“Regulators promoting RAS/ERK and mTORC signaling harbor gain-of-function mutations in many human cancers (Shaw and Cantley 2006; FernándezMedarde and Santos 2011), underscoring the importance of these pathways in promoting growth.”
Designer Therapies for Glioblastoma Multiforme
Sathornsumetee, S., & Rich, J. N. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1444.009 · Cited by 125
PSAT1 regulates cyclin D1 degradation and sustains proliferation of non‐small cell lung cancer cells
Yang, Y., Wu, J., Cai, J., He, Z., Yuan, J., Zhu, X., Li, Y., Li, M., & Guan, H. (2015) · International Journal of Cancer · doi:10.1002/ijc.29150 · Cited by 107
“Malignant tumor is essentially a disease involving unlimited cell proliferation.(1,2) To obtain limitless replicative potential, cancer cells not only need to sustain growth-stimulatory signals, but also must circumvent powerful anti-proliferative limits.”
BackgroundAutophagic pathways as new targets for cancer drug development
Liu, B., Cheng, Y., Liu, Q., Bao, J.-K., & Yang, J.-M. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.118 · Cited by 110
Vila-Bedmar, R., Lorenzo, M., & Fernández-Veledo, S. (2010) · Endocrinology · doi:10.1210/en.2009-0810 · Cited by 107
RIPK3 promotes kidney fibrosis via AKT-dependent ATP citrate lyase
Imamura, M., Moon, J., Chung, K., Nakahira, K., Muthukumar, T., Shingarev, R. A., Ryter, S. W., Choi, A. M. K., & Choi, M. E. (2018) · JCI Insight · doi:10.1172/jci.insight.94979 · Cited by 114
“AKTi may have multiple targets, such as mTOR signaling (44, 45), in addition to inhibiting the ACL pathway.”
BackgroundTight Junctions: A Barrier to the Initiation and Progression of Breast Cancer?
Brennan, K., Offiah, G., McSherry, E. A., & Hopkins, A. M. (2010) · BioMed Research International · doi:10.1155/2010/460607 · Cited by 120
“[102] R.”
Diagnosis and Treatment of High-Grade Astrocytoma
Sathornsumetee, S., Rich, J. N., & Reardon, D. A. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.004 · Cited by 128
Self-Assembly of Lithographically Patterned Nanoparticles
Cho, J., & Gracias, D. H. (2009) · Nano Letters · doi:10.1021/nl9022176 · Cited by 115
Rivera, V. M., Squillace, R. M., Miller, D., Berk, L., Wardwell, S. D., Ning, Y., Pollock, R., Narasimhan, N. I., Iuliucci, J. D., Wang, F., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0792 · Cited by 104
“org Mol Cancer Ther; 10(6) June 2011 1067”
BackgroundInfluentialA Genomic Strategy to Elucidate Modules of Oncogenic Pathway Signaling Networks
Chang, J. T., Carvalho, C., Mori, S., Bild, A. H., Gatza, M. L., Wang, Q., Lucas, J. E., Potti, A., Febbo, P. G., West, M., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.02.030 · Cited by 107
“Ras controls numerous processes related to cell proliferation and fate through interactions with secondary effectors (Shaw and Cantley, 2006).”
Lack of Hypoxic Response in Uterine Leiomyomas despite Severe Tissue Hypoxia
Mayer, A., Höckel, M., Wree, A., Leo, C., Horn, L., & Vaupel, P. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6339 · Cited by 113
“Diagrams illustrating these mechanisms have been presented recently (32, 37), and elements relevant to this discussion have been compiled within Fig.”
BackgroundmTOR at the crossroads of T cell proliferation and tolerance
Mondino, A., & Mueller, D. L. (2007) · Seminars in Immunology · doi:10.1016/j.smim.2007.02.008 · Cited by 108
Should individual PI3 kinase isoforms be targeted in cancer?
Jia, S., Roberts, T. M., & Zhao, J. J. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.007 · Cited by 122
“Differing requirements for PIK3CA and PIK3CB in murine cancer models driven by oncogenic RTKs, Ras, and PI3K Mutations are found in either one of various RTKs and/ or in their proximal downstream signaling components including Ras, Raf, and PI3K signaling pathways in most human cancers [16,64,65].”
BackgroundResveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells
de Brito, P. M., Devillard, R., Nègre‐Salvayre, A., Almeida, L. M., Dinis, T. C. P., Salvayre, R., & Augè, N. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.11.011 · Cited by 107
“The Ser/Thr kinase mTOR is implicated in spatial and temporal aspects of cell growth, controlling translation and cell cycle progression by phosphorylating 4EBP1 protein family and S6 protein kinases [6,7].”
BackgroundBeaver, J. A., Gustin, J. P., Yi, K. H., Rajpurohit, A., Thomas, M. C., Gilbert, S. F., Rosen, D. M., Park, B. H., & Lauring, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0884 · Cited by 130
“Signaling through the PI3K/AKT/mTOR pathway is critical to normal and malignant cellular processes, including proliferation, apoptosis, and metabolism (1, 2).”
Raha, S., Yumnam, S., Hong, G. E., Lee, H. J., Saralamma, V. V. G., Park, H.-S., Heo, J., Lee, S. J., Kim, E. H., Kim, J., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3095 · Cited by 106
“PI3K/Akt (protein kinase B)/mTOR (mammalian target of rapamycin) cascade is probably the most frequently altered signaling pathway in cancer (7).”
BackgroundCircadian regulation of ion channels and their functions
Ko, G. Y. ‐., Shi, L., & Ko, M. L. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06223.x · Cited by 103
Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
Cidado, J. R., & Park, B. H. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9264-2 · Cited by 120
Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus
Wu, T., Qin, X., Kurepa, Z., Kumar, K. R., Liu, K., Kanta, H., Zhou, X. J., Satterthwaite, A. B., Davis, L. S., & Mohan, C. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30398 · Cited by 108
“AKT is a serine/threonine kinase that regulates cell growth, survival, metabolism, and cell-cycle progression (31).”
BackgroundGrowth factor signaling to mTORC1 by amino acid–laden macropinosomes
Yoshida, S., Pacitto, R., Yao, Y., Inoki, K., & Swanson, J. A. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201504097 · Cited by 105
“M-CSF also transiently increased the activities of MAP kinase/ERK kinase (MEK) and extracellular signal–related kinase (ERK) (MEK/ERK), PI3K, and mTORC2, another mTOR complex (Loewith et al., 2002; Shaw and Cantley, 2006).”
BackgroundBai, H., Li, H., Li, W., Gui, T., Yang, J., Cao, D., & Shen, K. (2015) · Oncotarget · doi:10.18632/oncotarget.4550 · Cited by 109
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy
Caino, M. C., & Altieri, D. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0460 · Cited by 105
“Supported by compelling experimental evidence (31), there have been high expectations that therapeutic targeting of the PI3K pathway could fulfill the goals of "personalized" cancer medicine.”
BackgroundTranslational control of aberrant stress responses as a hallmark of cancer
El-Naggar, A. M., & Sorensen, P. H. B. (2018) · The Journal of Pathology · doi:10.1002/path.5030 · Cited by 114
Li, Q., Zhu, C., Ni, B., Zhang, Z., Jiang, S., Hu, L.-P., Zhang, X.-X., Zhang, X.-X., Huang, P.-Q., Yang, Q., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.037 · Cited by 111
The FoxO–BNIP3 axis exerts a unique regulation of mTORC1 and cell survival under energy stress
Lin, A., Yao, J., Zhuang, L., Wang, D., Han, J., Lam, E. W.-F., TCGA Research Network, & Gan, B. (2014) · Oncogene · doi:10.1038/onc.2013.273 · Cited by 103
Targeting mTOR network in colorectal cancer therapy
Wang, X.-W. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4178 · Cited by 100
Wang, Z., Wang, N., Liu, P., & Xie, X. (2016) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-319-43589-3_9 · Cited by 124
Receptor signaling as a regulatory mechanism of DNA repair
Meyn, R. E., Munshi, A., Haymach, J. V., Milas, L., & Ang, K. K. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.06.031 · Cited by 111
“[37–39] Using a selective inhibitor of IGF1R tyrosine kinase activity, tyrphostin AG 1024, Wen et al.”
MethodCritical roles for the TSC-mTOR pathway in β-cell function
Mori, H., Inoki, K., Opland, D., Münzberg, H., Villanueva, E. C., Faouzi, M., Ikenoue, T., Kwiatkowski, D. J., MacDougald, O. A., Myers, M. G., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00262.2009 · Cited by 103
“Insulin and insulin-like growth factor I potently activate mTOR likely through the phosphatidylinositol 3-kinase (PI3K) and Akt pathways (34).”
BackgroundmTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice
Thiem, S., Pierce, T. P., Palmieri, M., Putoczki, T. L., Buchert, M., Preaudet, A., Farid, R. O., Love, C., Catimel, B., Lei, Z., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65086 · Cited by 105
“Excessive mTORC1 activity is commonly observed in human cancers harboring mutations that activate the PI3K pathway (16, 17, 61).”
Porta, C., & Figlin, R. A. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.08.085 · Cited by 110
Chemoprevention and Treatment of Experimental Cowden's Disease by mTOR Inhibition with Rapamycin
Squarize, C. H., Castilho, R. M., & Gutkind, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0922 · Cited by 102
“Reduced PTEN function, and thus elevated PIP3 accumulation, can result in altered activity of a PI3K-depedent signaling network, which ultimately promotes disease progression (21, 22 ).”
BackgroundInfluentialBetulinic acid and the pharmacological effects of tumor suppression
Zhang, X., Hu, J., & Chen, Y. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5792 · Cited by 112
“The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, integrating extra-and intracellular survival signals, stimulates cell growth and inhibits cell death (73,74).”
Cancer cell metabolism and the modulating effects of nitric oxide
Chang, C.-F., Diers, A. R., & Hogg, N. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.012 · Cited by 102
PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
He, Y., Van't Veer, L. J., Mikolajewska-Hanclich, I., van Velthuysen, M.-L. F., Zeestraten, E. C. M., Nagtegaal, I. D., van de Velde, C. J. H., & Marijnen, C. A. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1165 · Cited by 100
“Many studies have implicated that PIK3CA mutations play a central role in tumorigenesis through the coordinated phosphorylation of proteins or transcription factors that directly regulate cell proliferation, differentiation, and invasion (13, 16).”
Liquid Chromatography–High Resolution Mass Spectrometry Analysis of Fatty Acid Metabolism
Kamphorst, J. J., Fan, J., Lu, W., White, E., & Rabinowitz, J. D. (2011) · Analytical Chemistry · doi:10.1021/ac202220b · Cited by 100
The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer
Cho, D., Signoretti, S., Regan, M. M., Mier, J. W., & Atkins, M. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1986 · Cited by 111
“1 and is reviewed in greater detail elsewhere (6).”
BackgroundShen, K., Choe, A., & Sabatini, D. M. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.026 · Cited by 101
“Diverse inputs, including amino acids, growth factors, and energy levels, converge on mTORC1 to regulate its kinase activity and signal to downstream effectors (Efeyan et al., 2015; González and Hall, 2017; Jewell et al., 2013; Shaw and Cantley, 2006).”
Targeting the CNS to treat type 2 diabetes
Sandoval, D. A., Obici, S., & Seeley, R. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2874 · Cited by 110
“Thus, hormonal signals of energy surplus, such as insulin, are known to induce phosphorylation of mTOR substrates in peripheral tissue”
BackgroundMechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells
Yue, W., Fan, P., Wang, J., Li, Y., & Santen, R. J. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.05.008 · Cited by 111
Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas
Tamborini, E., Virdis, E., Negri, T., Orsenigo, M., Brich, S., Conca, E., Gronchi, A., Stacchiotti, S., Manenti, G., Casali, P. G., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq003 · Cited by 107
Coward, J., Ambrosini, G., Musi, E., Truman, J., Haimovitz‐Friedman, A., Allegood, J. C., Wang, E. L., Merrill, A. H., & Schwartz, G. K. (2009) · Autophagy · doi:10.4161/auto.5.2.7361 · Cited by 101
Kim, H. J., Kwon, H., Lee, J. W., Kim, H. J., Lee, S. B., Park, H. S., Sohn, G., Lee, Y., Koh, B. S., Yu, J. H., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0574-3 · Cited by 101
Bender, A., Opel, D., Naumann, I., Kappler, R., Friedman, L. S., von Schweinitz, D., Debatin, K., & Fulda, S. (2010) · Oncogene · doi:10.1038/onc.2010.429 · Cited by 107
Wen, P. Y., Cloughesy, T. F., Olivero, A. G., Morrissey, K. M., Wilson, T. R., Lu, X., Mueller, L. U., Coimbra, A. F., Ellingson, B. M., Gerstner, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2808 · Cited by 96
“org Clin Cancer Res; 26(8) April 15, 2020 1823”
BackgroundInfluentialPuig, T., Aguilar, H., Cufí, S., Oliveras, G., Turrado, C., Ortega-Gutiérrez, S., Benhamú, B., López-Rodríguez, M. L., Urruticoechea, A., & Colomer, R. (2011) · Breast Cancer Research · doi:10.1186/bcr3077 · Cited by 96
Tanboon, J., Williams, E. A., & Louis, D. N. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlv009 · Cited by 103
Recent advances in lipidomics for disease research
Li, Y., Li, M., Shan, Y., Shen, S., Bai, Y., & Liu, H. (2015) · Journal of Separation Science · doi:10.1002/jssc.201500899 · Cited by 108
Autophagy genes as tumor suppressors
Liang, C., & Jung, J. U. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.11.003 · Cited by 105
“Put simply, the oncogenic components in the PI3K-Akt-mTOR-mediated anabolic pathway are constitutively active in most cancers, whereas molecules known to suppress mTOR, including PTEN, AMPK, and TSC1/TSC2, are often mutated [42].”
Backgroundβ-TrCP-Mediated Ubiquitination and Degradation of PHLPP1 Are Negatively Regulated by Akt
Li, X., Liu, J., & Gao, T. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00681-09 · Cited by 99
“Hyperactivation of phosphatidylinositol 3-kinase/Akt signaling is commonly associated with human cancers (1, 5, 27).”
BackgroundKong, D., Banerjee, S., Huang, W., Li, Y., Wang, Z., Kim, H.-R. C., & Sarkar, F. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3241 · Cited by 102
Ye, R., Dai, N., He, Q., Guo, P., Xiang, Y., Zhang, Q., Hong, Z., & Zhang, Q. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.065 · Cited by 100
Autophagy: Highlighting a novel player in the autoimmunity scenario
Lleò, A., Invernizzi, P., Selmi, C. F., Coppel, R. L., Alpini, G. D., Podda, M., Mackay, I. R., & Gershwin, M. E. (2007) · Journal of Autoimmunity · doi:10.1016/j.jaut.2007.06.003 · Cited by 102
PHLPP-Mediated Dephosphorylation of S6K1 Inhibits Protein Translation and Cell Growth
Liu, J., Stevens, P. D., Li, X., Schmidt, M. D., & Gao, T. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05799-11 · Cited by 92
“Hyperactivation of the PI3K/Akt/mTOR signaling pathway is one of the major driving forces in promoting tumorigenesis (6, 28).”
BackgroundGrewal, S. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.12.005 · Cited by 107
LKB1/AMPK/mTOR Signaling Pathway in Non-small-cell Lung Cancer
Han, D., Li, S.-J., Zhu, Y.-T., Liu, L., & Li, M.-X. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.7.4033 · Cited by 95
“, 2009) and NSCLC (Shaw and Cantley, 2006; Ji et al., 2007).”
BackgroundKieran, M. W., Gordon, L., & Kleinman, M. (2007) · Pediatrics · doi:10.1542/peds.2007-1356 · Cited by 99
Agarwal, S., Bell, C. M., Rothbart, S. B., & Moran, R. G. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.665133 · Cited by 103
“The mammalian target of rapamycin (mTOR)(2) is a highly conserved regulator of cell growth and proliferation in mammalian cells that is often dysregulated in human carcinomas (1, 2).”
BackgroundDiscovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α
Zunder, E. R., Knight, Z. A., Houseman, B. T., Apsel, B., & Shokat, K. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.014 · Cited by 95
“…members, including receptor tyrosine kinases (RTKs), Ras, PTEN, and Akt, are frequently mutated instead (Brugge et al., 2007; Cully et al., 2006; Shaw and Cantley, 2006), high-lighting the critical role that PI3K signaling plays in oncogenesis and tumor maintenance (Gupta et al., 2007; Lim and…”
The unconventional role of Akt1 in the advanced cancers and in diabetes-promoted carcinogenesis
Alwhaibi, A. M., Verma, A., Adil, M. S., & Somanath, P. R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104270 · Cited by 98
Metadata
- Authors
- Shaw, R. J., & Cantley, L. C.
- Affiliations
- Salk Institute for Biological Studies (US)
- Beth Israel Deaconess Medical Center (US)
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 424-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2144323242
- Cited by
- 2,019
- References
- 86
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 48 · 2023: 68 · 2022: 68 · 2021: 77 · 2020: 91 · 2019: 74 · 2018: 95 · 2017: 99 · 2016: 109 · 2015: 146 · 2014: 119 · 2013: 153 · 2012: 143
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041890)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- Ras signaling, PI3K signaling, mTOR signaling, tumour cell growth, nutrient sensing, amino acids, glucose, oxygen availability, cancer mutations, carcinogenesis, cell survival
- MeSH terms
- Animals, Humans, Neoplasms, Protein Kinases, Signal Transduction, ras Proteins, Phosphatidylinositol 3-Kinases, Cell Growth Processes, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.